Subsequent studies with clinical data in EGFR mutant NSCLC were inconsistent regarding the predictive role of BIM deletion polymorphism with respect to the responsiveness to first‐generation EGFR‐TKIs. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.